Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4Philadelphia Chromosome 2Ovarian Neoplasms 2Neoplasms 2Myeloproliferative Disorders 2Recurrence 1Peritoneal Neoplasms 1Neoplasm Metastasis 1Leukemia 1Genital Neoplasms, Female 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Cholangiocarcinoma 1Breast Neoplasms 1Blast Crisis 1Appendiceal Neoplasms 1

Interventions

Fulvestrant 26Letrozole 25Specimen Handling 19ribociclib 18Capecitabine 16pembrolizumab 15palbociclib 13Trastuzumab 13Paclitaxel 13abemaciclib 12Tamoxifen 12Anastrozole 12exemestane 11Magnetic Resonance Spectroscopy 11trastuzumab deruxtecan 10Carboplatin 10Biopsy 9pertuzumab 8Goserelin 8inavolisib 6Standard of Care 6Cyclophosphamide 6olaparib 5giredestrant 5elacestrant 5Taxes 5Radiotherapy 5Radiation 5130-nm albumin-bound paclitaxel 5pyrotinib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Breast Neoplasms × nilotinib × 30 days × Clear all
NCT05185947 2026-05-29

Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
21 enrolled 21 charts
BreastGastrointestinalGynecologic

Appendiceal Neoplasms, Breast Neoplasms, Genital Neoplasms, Female, Ovarian Neoplasms, Peritoneal Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡